Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant DiseaseSEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Brokerages expect that Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Rating) will report ($1.24) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for Aptevo Therapeutics’ earnings. The lowest EPS estimate is ($1.54) and the highest is ($0.93). Aptevo Therapeutics reported earnings per share of ($1.74) in the same quarter […]
Brokerages expect that Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Rating) will post sales of $3.75 million for the current quarter, Zacks reports. Two analysts have made estimates for Aptevo Therapeutics’ earnings, with estimates ranging from $3.50 million to $4.00 million. Aptevo Therapeutics reported sales of $2.42 million in the same quarter last year, which would […]
Aptevo Therapeutics (NASDAQ:APVO – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Zacks.com reports. The firm presently has a $6.75 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 14.41% […]